Vaccine makers' legal shield questioned; Struggling Cell Therapeutics sells drug rights;

> Now that vaccines have become one of Big Pharma's biggest growth engines, should vaccine makers continue to wear a legal shield? FiercePharma

> Cell Therapeutics struck a deal to sell its remaining 50 percent stake in the cancer drug Zevalin for $18 million as it struggles to avoid running out of cash. Spectrum Pharmaceuticals--which already owns half of the drug--bought the remaining rights. FierceBiotech

> According to new information from Global Industry Analysts, the global hospital information systems market will grow beyond $35 billion by the year 2015. The growth should be driven largely by increased U.S. hospitals, the largest market in the world. FierceHealthIT

And Finally... Now, at least, this woman can send her nephew a present. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.